Everolimus (EVL), a specific oral mTOR inhibitor, has been approved by the U.S. Food and Drug Administration to treat various cancers, such as breast cancer, pancreatic cancer and renal cell carcinoma32. This evidence concerns the gene MTOR and breast cancer.